News | December 12, 2022
Lupin launches generic version of Pennsaid in the US
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
This product is based on Osmotic Controlled Release Oral Delivery System technology
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Revenue from operations up 26% to Rs. 768 crores
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Subscribe To Our Newsletter & Stay Updated
